CMX 020

Drug Profile

CMX 020

Alternative Names: CMX020

Latest Information Update: 19 Oct 2016

Price : $50

At a glance

  • Originator Cmxtwenty
  • Class Arachidonic acids; Non-opioid analgesics
  • Mechanism of Action Cannabinoid receptor CB1 modulators; Cannabinoid receptor CB2 modulators; TRPV1 receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Neuropathic pain
  • Phase I Postoperative pain

Most Recent Events

  • 14 Oct 2016 Cmxtwenty plans a phase II trial in Pain due to osteoarthritis in Australia (ACTRN12616001435471p)
  • 08 Jun 2016 Cytometix withdrew a phase I trial, prior to enrolment, for Pain (In volunteers) in Australia (IV, Infusion) before June 2016 (ACTRN12615001255572p)
  • 01 Jun 2016 Cmxtwenty completes a phase-II clinical trial in Neuropathic pain (In adults, In the elderly) in Australia (PO) (ACTRN12615000885594)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top